The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumQuick Picks - While Discovery Laboratories (NASDAQ:DSCO) maintains that Afectair will hit the market in December, the launch of Surfaxin has been delayed until at least the second … Continue Reading
Read nowQuick Picks - Price targets are rising for Questcor Pharmaceuticals (NASDAQ:QCOR) on Wednesday following the company’s third quarter earnings beat. The revised sell-side expectations support PropThink’s target price … Continue Reading
Read nowQuick Picks - United Therapeutics Corporation (NADSAQ:UTHR) announced after hours on Tuesday that it’s application for an oral formulation of Remodulin (treprostinil) received a Complete Response Letter (CRL) from the … Continue Reading
Read nowLong Ideas - Palifosfamide is a bifunctional alkylator developed by Ziopharm Oncology (NASDAQ:ZIOP) for the treatment of a number of cancers. Soft tissue sarcoma (STS) is the most … Continue Reading
Read nowLong Ideas - Questcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … Continue Reading
Read nowLong Ideas - Shares of ARIAD Pharmaceuticals (NASDAQ:ARIA) were under pressure Tuesday following a downgrade from Oppenheimer, which lowered ARIA from Outperform to Perform with a $23 price … Continue Reading
Read nowLong Ideas - Amarin Corp. (NASDAQ:AMRN) got a bump in the pre-market Tuesday after announcing that two more patents have been added to Vascepa’s Intellectual Property, protecting the … Continue Reading
Read now
